Role of blood coagulation factor XIII in patients with acute pulmonary embolism. Correlation of factor XIII antigen levels with pulmonary occlusion rate, fibrinogen, D-dimer, and clot firmness

Summary

In patients with acute pulmonary embolism (PE), pulmonary occlusion rate is directly related to D-dimer and inversely related to fibrinogen levels. The role of coagulation factor XIII (FXIII) levels in acute venous thromboembolism is not known. A total of 120 consecutive patients with suspected PE and VIDAS D-dimer levels >500 μg/L were investigated by helical computed tomography (CT). Pulmonary occlusion rate was assessed by CT using the modified Miller index. D-dimer, fibrinogen, and FXIII A- and B-subunit antigen levels were taken on admission. Thrombelastography (TEG) was performed in a subset of patients (n=12).

The 71 patients with PE had lower FXIII A-subunit levels than the 49 patients with excluded PE (78.6±24.5% vs. 91.3±28.8%, p=0.01). In both groups, FXIII A-subunit was inversely related to D-dimer levels. FXIII A-subunit correlated with fibrinogen levels in patients with PE but not in patients without PE. FXIII A-subunit decreased with increasing pulmonary occlusion rate. The risk of PE was increased in the presence of A-subunit levels < 60% (OR 7.0 [95% CI 1.4-35.3], p=0.019). Clot firmness determined by TEG was lower in patients with PE than in patients without PE.

In patients with PE, circulating FXIII A-subunit is decreased compared to patients with suspected but excluded PE. The higher the clot burden within the pulmonary arteries the lower the FXIII antigen. In these patients, direct relation of FXIII A-subunit to fibrinogen levels argues for significant consumption of these coagulation factors in PE. This consumption of FXIII can also be detected by a global coagulation test like TEG.

Keywords

Coagulation factor XIII - D-dimer - fibrinogen - pulmonary embolism - thrombelastography

• References

• 1 Kohler HP, Grant PJ. Role of FXIIIVal34Leu in cardiovascular disease [Review]. Q J Med 1999; 92: 67-72.
• 2 Kohler HP. Role of blood coagulation factor XIII in vascular diseases [Review] . Swiss Med Wkly 2001; 131: 31-4.
• 3 Ichinose A. The physiology and biochemistry of factor XIII. In: Haemostasis and Thrombosis. Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD. eds, 3rd edn, Vol. 1 Edinburg: Livingstone; 1994: 531-46.
• 4 Valnickova Z, Enghild JJ. Human procarboxypeptidase U, or thrombin-activatable fibrinolysis inhibitor, is a substrate for transglutaminases. J Biol Chem 1998; 273: 27220-4.
• 5 Riedel M. Venous thromboembolic disease. Acute pulmonary embolism 1: pathophysiology, clinical presentation, and diagnosis [Review]. Heart 2001; 85: 229-40.
• 6 Goldhaber SZ. Pulmonary embolism [Review]. N Engl J Med 1998; 339: 93-104.
• 7 Reed GL, Houng AK. The contribution of activated factor XIII to fibrinolytic resistance in experimental pulmonary embolism. Circulation 1999; 99: 299-304.
• 8 Kucher N, Kohler HP, Dornhöfer T. et al. Accuracy of D-dimer/fibrinogen ratio to predict pulmonary embolism: a prospective diagnostic study. J Thromb Haemost 2003; 1: 708-13.
• 9 Schroeder V, Chatterjee T, Kohler HP. Influence of blood coagulation factor XIII and FXIII Val34Leu on plasma clot formation measured by thrombelastography. Thromb Res 2001; 104: 467-74.
• 10 Wells PS, Ginsberg JS, Anderson DR. et al. Use of a clinical model for safe management of patients with suspected pulmonary embolism. Ann Intern Med 1998; 129: 997-1005.
• 11 Remy-Jardin M, Louvegny S, Remy J. et al. Acute central thromboembolic disease: post-therapeutic follow-up with spiral CT angiography. Radiology 1997; 203: 173-80.
• 12 Ariëns RAS, Kohler HP, Mansfield MW, Grant PJ. Subunit antigen and activity levels of blood coagulation factor XIII in healthy individuals. Relation to sex, age, smoking and hypertension. Arterioscler Thromb Vasc Biol 1999; 19: 2012-6.
• 13 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-46.
• 14 Kohler HP, Ariëns RAS, Mansfield MW, Whitaker P, Grant PJ. Factor XIII activity and antigen levels in patients with coronary artery disease. Thromb Haemost 2001; 85: 569-70.
• 15 Lorand L. Factor XIII: Structure, activation, and interactions with fibrinogen and fibrin. Ann N Y Acad Sci 2001; 936: 291-311.